Q&A with Center Health Equity Fellow
As her Health Equity Fellowship comes to a close, we’re proud to spotlight Dominique Seo, PhD candidate in Pharmaceutical Health Services Research at the University of Maryland, Baltimore. Over the past year, Dominique has brought deep expertise in pharmacoeconomics, with a focus on drug pricing, access, and health disparities, to the IVI. We sat down […]
Center Statement re: Trump’s Ultimatum on MFN
IVI shares the public’s urgency in addressing the affordability of prescription drugs and healthcare in the United States. However, as momentum builds around aggressive policy proposals like the Most Favored Nation (MFN) pricing model, we urge policymakers to pause and ask a critical question: What do these policies mean for patients? As we have emphasized in […]
Redefining Value: Asia Williams on Building Trust and Advancing Through Community Engagement
Asia Williams, MPH, Program Officer at the National Academy of Medicine’s Leadership Consortium, leads the Trust & Engagement Action Collaborative, where she works to strengthen trust and elevate community voices in healthcare systems. With a background in public health, quality improvement, and patient engagement, she brings both personal and professional insight to the urgent need for meaningful community partnerships.
IVI Comments on the CMS Draft Guidance for the Medicare DPNP
IVI submitted comments on the draft guidance on the Medicare Drug Price Negotiation Program published on May 12, 2025.
IVI Responds to MFN Executive Order
Advancing patient-centered, evidence-based policy Alexandria, VA – May 13, 2025 – IVI released the following statement: IVI shares the goal of ensuring patients have affordable access to needed therapies. Controlling healthcare costs is essential to maintaining that access. However, the Most Favored Nation (MFN) pricing model is a blunt instrument that imports foreign price controls […]
Join IVI at ISPOR 2025
We are excited to present our research at ISPOR 2025 in Montreal, where our posters will contribute to the global dialogue on health economics and outcomes research (HEOR). In alignment with this year’s theme, “Collaborating to Improve Healthcare Decision Making for All: Expanding HEOR Horizons,” our work explores innovative methodologies and real-world data applications aimed […]
PRESS RELEASE: IVI Announces CEO Transition
IVI today announced that Dr. Jason Spangler has made the decision to step down as President and Chief Executive Officer, effective April 30, 2025.
Centering Caregivers in Rare Disease: Elevating Their Role in Patient-Centered Research and Advocacy
Authors: Dominque Seo, MPH, Gloria Rodriguez, MPH, Michelle Cheng, MHS While any single rare condition affects a relatively small population, collectively, rare diseases impact over 30 million Americans, which represents significant health impacts for individuals and families.1 At the heart of many patients’ health journeys are caregivers, who take on substantial responsibilities. Caregivers offer crucial […]
A Journey Through Pain and Mistrust: One Patient’s Fight for Dignity and Care
Elizabeth L. Cope, PhD, MPH, sheds light on the profound physical and emotional toll of a misdiagnosed and misunderstood health journey. Her story highlights the urgent need for a healthcare system that offers treatment and compassionate support. Through years of navigating stigma and mistrust, Elizabeth emerges as a fierce advocate for systemic change, fighting for a healthcare system that truly sees and serves those in need.
Understanding HTA: Why Health Technology Assessment Matters for Patients
By Xanthia Lam, MPH (May 2025), Patient Engagement Intern at IVI IVI (Center) is a non-profit research organization whose mission is to advance the science, use, and practice of Patient-Centered Health Technology Assessment to support decisions that make healthcare more meaningful and equitable. However, as Health Technology Assessment is a niche topic and field, it […]